Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Elkins

Showing results (261-270 of 352) with videos related to

Pageof 36
Sort By:
Revista Brasileira De Fisioterapia (Sao Carlos (Sao Paulo, Brazil))|August 24, 2010
Endorsement of trial registration and the CONSORT statement by the Revista Brasileira de FisioterapiaLeonardo O P Costa, Christopher G Maher, Anne M Moseley, et al.
Journal of Virology|March 9, 2000
A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primatesJ E Bailly, J M McAuliffe, A P Durbin, et al.
Vaccine|June 1, 1995
Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunizationJ E Crowe, P T Bui, G R Siber, et al.
Journal of Virology|April 1, 1994
Spontaneous substitutions in the vicinity of the V3 analog affect cell tropism and pathogenicity of simian immunodeficiency virusV M Hirsch, J E Martin, G Dapolito, et al.
Vaccine|June 17, 2000
Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challengeR Men, L Wyatt, I Tokimatsu, et al.
Respiratory Care|April 18, 2013
The quality and reporting of randomized trials in cardiothoracic physical therapy could be substantially improvedNádia N Geha, Anne M Moseley, Mark R Elkins, et al.
Comparative Medicine|March 7, 2023
Contributions of Diet and Age to Ulcerative Dermatitis in Female C57BL/6J MiceAlfonso S Gozalo, Patricia M Zerfas, Jing Qin, et al.
Research on Child and Adolescent Psychopathology|June 15, 2021
Identifying the Inter-Domain Relations Among ODD, CD, and CU Traits in Preschool Children Using Network AnalysisPevitr S Bansal, Patrick K Goh, Ashley G Eng, et al.
CA: a Cancer Journal for Clinicians|January 29, 2013
Risk factors, pathophysiology, and treatment of hot flashes in cancerWilliam I Fisher, Aimee K Johnson, Gary R Elkins, et al.
Vaccine|March 22, 2002
The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeysMario H Skiadopoulos, Joanne M Tatem, Sonja R Surman, et al.
Pageof 36

Showing results (261-270 of 352) with videos related to

Sort By:
Pageof 36
Revista Brasileira De Fisioterapia (Sao Carlos (Sao Paulo, Brazil))|August 24, 2010
Endorsement of trial registration and the CONSORT statement by the Revista Brasileira de FisioterapiaLeonardo O P Costa, Christopher G Maher, Anne M Moseley, et al.
Journal of Virology|March 9, 2000
A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primatesJ E Bailly, J M McAuliffe, A P Durbin, et al.
Vaccine|June 1, 1995
Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunizationJ E Crowe, P T Bui, G R Siber, et al.
Journal of Virology|April 1, 1994
Spontaneous substitutions in the vicinity of the V3 analog affect cell tropism and pathogenicity of simian immunodeficiency virusV M Hirsch, J E Martin, G Dapolito, et al.
Vaccine|June 17, 2000
Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challengeR Men, L Wyatt, I Tokimatsu, et al.
Respiratory Care|April 18, 2013
The quality and reporting of randomized trials in cardiothoracic physical therapy could be substantially improvedNádia N Geha, Anne M Moseley, Mark R Elkins, et al.
Comparative Medicine|March 7, 2023
Contributions of Diet and Age to Ulcerative Dermatitis in Female C57BL/6J MiceAlfonso S Gozalo, Patricia M Zerfas, Jing Qin, et al.
Research on Child and Adolescent Psychopathology|June 15, 2021
Identifying the Inter-Domain Relations Among ODD, CD, and CU Traits in Preschool Children Using Network AnalysisPevitr S Bansal, Patrick K Goh, Ashley G Eng, et al.
CA: a Cancer Journal for Clinicians|January 29, 2013
Risk factors, pathophysiology, and treatment of hot flashes in cancerWilliam I Fisher, Aimee K Johnson, Gary R Elkins, et al.
Vaccine|March 22, 2002
The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeysMario H Skiadopoulos, Joanne M Tatem, Sonja R Surman, et al.
Pageof 36